% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • remd659 remd659 Mar 3, 2013 9:51 PM Flag

    Ckd patients on dialysis.

    Thankful for every added day of life. Those on omontys 25000+ accepted the minuscule risks of their treatments and probably will continue when it returns.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • De Nile is a river in Egypt.

      Ask yourself one basic question: if a loved one were such a patient and asked you whether to use industry standard EPO or new-fangled killer O, which would you suggest. It's that simple. Game OVER.

      My sympathies to long term holders. New buyers here are just plain chumps.

      • 3 Replies to thegreycorner
      • Let me tell you about "loved ones." Patients make terrible physicians, and loved ones make the worst physicians. I see them keeping mommy and daddy alive , willing to intubate 2nd and third time. never accepting the fact that their cripple, desitute, aphasic, non responsive to stimuli loved one will never get well...... alll because they make terrible phuysicians. And sometimes they do it to keep collecting "the checks." watching, witing for a dr or nurse to mess up to file legal action. I call these people double american blood suking failures They suck the blood of their "loved ones bank rolll and medicade system, and adulterate them both.
        One day , when we wake up and do not have the basic health coverage needed, they will realize their folly. jmo. big changes dead ahead.

        Sentiment: Hold

      • Logic evades you once again. What you have given is a false choice. The "industry standard" or the "new-fangled killer". Please provide us with your final, scientific investigation into the cause of these deaths. Until then you are all cliche, no substance and shouldn't be taken seriously.

      • I agree, I would love to give you some epogen:

        A new study has found that using the anemia medications Epogen and Procrit may cause extensive heart damage when taken after a heart attack. The compelling research has called the use of such drugs into question, as the risks seem to heavily outweigh any possible benefit. Last year, the FDA announced that it was restricting the prescription of both Epogen and Procrit under a risk evaluation and mitigation strategy (REMS) to identify high risk users and negative side effects.

        The study involved 222 patients given either Epogen or Procrit or a placebo, and found that there was no difference in efficacy when it came to the prevention of heart attacks or the treatment of heart tissue damage from previous attacks. However, five participants who took the drugs experienced new heart attacks, blocked arteries, or died. None of the patients given placebos experienced any adverse side effects. The new JAMA study seems to support prior research suggesting that Epogen and Procrit may increase the risk of heart attacks, strokes, blood clots and death.

0.0771-0.0089(-10.35%)Aug 31 3:45 PMEDT